DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Gravita India Limited — Outcome of Board Meeting

NSE 1 hr ago·27 Oct 2026, 12:23 pm

Gravita India

Gravita India Limited has informed the stock exchanges regarding its financial results for the period ending September 30, 2026. The company has submitted these details to ensure transparency and compliance with regulatory norms. This update is part of the standard corporate disclosure process for listed entities.

For investors, this announcement signals that the company is moving forward with its regular reporting cycle. It provides an opportunity to review the firm's operational performance and financial health. While the specific figures are not yet detailed, the submission confirms that the company is adhering to its reporting obligations.

Investors should look out for the detailed financial statements and management commentary in the official exchange filing. This information will be crucial for assessing the company's current trajectory and future prospects.